Quizartinib (Vanflyta, Daiichi Sankyo) is indicated 'in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3‑ITD positive'.
The dosage schedule is available in the summary of product characteristics for quizartinib.
The list prices of quizartinib are £6,451 for a 28‑pack of 17.7 mg tablets, and £12,902 for a 56‑pack of 26.5 mg tablets (excluding VAT; BNF online accessed August 2024).
The company has a commercial arrangement. This makes quizartinib available to the NHS with a discount. The size of the discount is commercial in confidence.